EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.

"S. Tao and Q. Wu are employees of Chengdu Kanghong Biotech, Inc, Z. Ke is employee of Chengdu Kanghong Pharmaceutical Group, Chengdu Kanghong Biotech, Inc, and Chengdu Kanghong Pharmaceutical Group participated in the design of the study, data collection, data management, data analysis, preparation of the manuscript. The remaining authors have no financial/conflicting interests to disclose."

"Supported by Chengdu Kanghong Biotech, Inc, Chengdu, Sichuan, China."

"The FALCON study was a Phase II, nonrandomized, noncontrolled, 9-month trial assessing the efficacy and safety of intravitreal injection of conbercept (IVC) in macular edema secondary to retinal vein occlusion. The study was conducted at two sites in China (The Affiliated Eye Hospital of Wenzhou Medical University and Beijing Tongren hospital affiliated to Capital Medical University). The study protocol was approved by each institutional review board or ethics committee. The study was carried out in adherence with guidelines established by the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. All patients provided written informed consent to participate in this trial. The FALCON study was registered with ClinicalTrials.gov (identifier no. NCT01809236). Data described here were collected between September 2012 and May 2014."